作者
Roberto Mina, Pellegrino Musto, Delia Rota-Scalabrini, Laura Paris, Barbara Gamberi, Angelo Palmas, Sara Aquino, Paolo de Fabritiis, Nicola Giuliani, Luca De Rosa, Alessandro Gozzetti, Claudia Cellini, Luca Bertamini, Andrea Capra, Daniela Oddolo, Iolanda Donatella Vincelli, Sonia Ronconi, Vincenzo Pavone, Norbert Pescosta, Michele Cea, Francesca Fioritoni, Stelvio Ballanti, Mariella Grasso, Elena Zamagni, Angelo Belotti, Mario Boccadoro, Francesca Gay
发表日期
2023/1/1
期刊
The Lancet Oncology
卷号
24
期号
1
页码范围
64-76
出版商
Elsevier
简介
Background
Patients with newly diagnosed multiple myeloma and high-risk cytogenetic abnormalities (HRCA) represent an unmet medical need. In the FORTE trial, lenalidomide and dexamethasone plus carfilzomib (KRd) induction resulted in a higher proportion of patients with at least a very good partial response as compared with carfilzomib, cyclophosphamide, and dexamethasone (KCd), and carfilzomib plus lenalidomide maintenance prolonged progression-free survival compared with lenalidomide maintenance. In this prespecified analysis of the FORTE trial, we described the outcomes of enrolled patients according to their cytogenetic risk.
Methods
The UNITO-MM-01/FORTE was a randomised, open-label, phase 2 trial done at 42 Italian academic and community practice centres, which enrolled transplant-eligible patients with newly diagnosed multiple myeloma aged 18–65 years. Eligible patients had …
学术搜索中的文章
R Mina, P Musto, D Rota-Scalabrini, L Paris, B Gamberi… - The Lancet Oncology, 2023